vimarsana.com

Page 32 - ஒப்புதல் வாக்குமூலம் கில்லர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Welcome To IANS Live - TopStory - Yet to receive SEC communication on Sputnik V approval: DRL

Photo Credit: IANS IANSLive Hyderabad, April 12 (IANS) Amid reports that the subject expert committee (SEC) has approved Dr. Reddy s Laboratories (DRL) application for the Russian vaccine candidate Sputnik V to tackle Coronavirus pandemic, the city-based company is yet to receive official communication about the approval. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 12-April-2021

AfriAg Global Plc - Result of GM and AQSE Regulatory Approval for Apollon

AfriAg Global Plc - Result of GM and AQSE Regulatory Approval for Apollon PR Newswire ( Company ) AQUIS REGULATORY APPROVAL TO ACQUIRE APOLLON The Company is pleased to announce that at the General Meeting of the Company held today, all resolutions were duly passed. The Company is also pleased to announce that AQSE Regulatory approval to be admitted to the AQSE Growth Market has now been received to acquire the entire issued share capital of Apollon Formularies Limited, and it is expected that admission to trading will commence tomorrow, 13 April 2021 at 8 a.m. The Enlarged Share Capital of 748,376,677 Ordinary Shares will be admitted to trading, comprising 31,710,011 Existing Ordinary Shares, 666,666,666 Consideration Shares and 50,000,000 Placing Shares and Subscription Shares.

CCI approval for Adar Poonawalla s firm to pick up 60% in Magma Fincorp

Welcome To IANS Live - NATION - India set to get third vaccine as expert panel clears Sputnik

After the Drug Controller General of India gives assent to the Subject Expert Committee s approval, the sources told IANS, India will have a third Covid vaccine after AstraZeneca-Oxford University developed-Serum Institute of India-manufactured Covishield and Bharat Biotech-developed and manufactured Covaxin.Indi

Biden faces the reality of creating a post-Trump agenda as political confrontations set over policy proposals

Biden faces the reality of creating a post-Trump agenda as political confrontations set over policy proposals Published April 12, 2021 KEVIN LAMARQUE/Reuters U.S. President Joe Biden has high approval ratings, high hopes, high-spending plans – and his high-risk policies are approaching a set of High Noon political confrontations. Congress is back from its Easter break this week and confronts a passel of Biden proposals costing many trillions of dollars. But though the Democrats control both houses on Capitol Hill, the President’s eye-popping initiatives face opposition from Republicans and dangerous skepticism among some Democrats in the Senate, where Mr. Biden cannot afford to lose a single vote in a 50-50 chamber with Vice-President Kamala Harris providing the tipping point.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.